Liver cancer is a devastating malignancy that poses a significant global health burden. With its high mortality rate and limited therapeutic options, liver cancer demands intensive research and innovative approaches. As a pioneer in the gastrointestinal cancer field, Alfa Cytology provides a complete solution for liver cancer.
Molecular Targets and Signal Pathways for Liver Cancer Therapy Development
Understanding the molecular targets and signal pathways involved in liver cancer is crucial for the development of effective therapies. Several key pathways have been identified as critical players in liver cancer progression and are being targeted for therapeutic interventions.
-
Ras signaling pathway
Mutations in Ras genes, particularly in KRAS, have been associated with liver cancer development. Targeting Ras signaling components and downstream effectors holds promise for inhibiting tumor growth and improving patient outcomes.
- Wnt/β-catenin signaling pathway
berrant activation of this pathway leads to the accumulation of β-catenin in the nucleus, resulting in uncontrolled cell proliferation. Therapeutic strategies aimed at modulating Wnt/β-catenin signaling hold potential for inhibiting tumor growth and metastasis.
- PI3K/Akt/mTOR pathway
Dysregulation of this pathway promotes cell survival, angiogenesis, and resistance to apoptosis. Targeted therapies that inhibit PI3K, Akt, or mTOR have shown promising results in preclinical and clinical studies, providing hope for improved treatment options.
Fig.1 Schematic representation of major signaling pathways involved in liver cancer. (Dimri, M., & Satyanarayana, A., 2020)
Therapy Development for Liver Cancer
Liver cancer is a significant global health concern, and the development of innovative diagnostic and therapeutic methods holds great market promise. The rising incidence of liver cancer, coupled with the need for improved detection and therapy, has created opportunities for advancements in this field. The global liver cancer treatment market size is expected to reach USD 2.44 billion by 2022, at a CAGR of 20.00%, and USD 10.48 billion by 2030. Liver cancer pipeline report is a robust space with 70+ active players working to develop 75+ pipeline therapies for liver cancer.
Our Services
This surge in market size underscores the increasing demand for effective and innovative therapy solutions. Alfa Cytology is devoted to developing more effective and personalized therapy for liver cancer. We provide one-stop solutions for salivary gland cancer, including but not limited to the following.
Modeling Services of Liver Cancer
Alfa Cytology specializes in providing various animal models tailored for liver cancer research. These models are valuable tools to study liver cancer etiology, progression, and therapy.
In Vitro Models
2D models
3D Co-cultures
|
In Vivo Models
Mouse models
- Chemically induced mouse Models
- Xenograft models
- Genetically engineered models (GEMs)
- Humanized models
Non-mouse models
- Rat model
- Zebrafish model
|
Computational Modeling
- In silico models
- Prediction using artificial intelligence
and machine learning methods
|
Alfa Cytology is committed to the research and study of cancer, from cell therapy development services, immune checkpoint inhibitor development services, to cancer drug development services, providing one-stop solutions. Our cancer experts have many years of experience in the development of the latest therapies for liver cancer. If you are interested in our service, please contact us.
Reference
- Dimri, M., & Satyanarayana, A. (2020). Molecular signaling pathways and therapeutic targets in hepatocellular carcinoma. Cancers, 12(2), 491.
For research use only.
Related Services
